This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:


peer-reviewed publication

trusted source


Link between COVID-19 vaccine complication and rare 'common cold' blood disease

Link between COVID-19 vaccine complication and rare 'common cold' blood disease
Shared fingerprints of anti-PF4 antibodies in VITT and VITT-like disorders after adenovirus infection. Credit: New England Journal of Medicine (2024). DOI: 10.1056/NEJMc2402592

New research led by Flinders University and international experts is expanding understanding of vaccine-induced immune thrombocytopenia and thrombosis (known as VITT).

At the height of the COVID-19 pandemic in 2021, VITT emerged as a new disease following adenovirus vector-based vaccines—notably the Oxford-AstraZeneca .

VITT was found to be caused by an unusually dangerous blood autoantibody directed against a protein termed platelet factor 4 (or PF4).

In separate research in 2023, researchers from Canada, North America, Germany and Italy described a virtually identical disorder with the same PF4 antibody that was fatal in some cases after natural adenovirus (common cold) infection.

Flinders University researchers Dr. Jing Jing Wang and Flinders Professor Tom Gordon, Head of Immunology at SA Pathology in South Australia, led a previous study in 2022 which cracked the molecular code of the PF4 antibody and identified a genetic risk factor related to an antibody gene termed IGLV3.21*02.

Now, the Flinders group has collaborated with this international group of researchers to find that the PF4 antibodies in both adenovirus infection-associated VITT and classic adenoviral vectored VITT share identical molecular fingerprints or signatures.

The research will also have implications for improving vaccine development, says Flinders University researcher Dr. Wang, first author on the article published in the New England Journal of Medicine and titled "Antibody Fingerprints Linking Adenoviral Anti-PF4 Disorders."

"These findings, using a completely new approach for targeting blood antibodies developed at Flinders University, indicate a common triggering factor on virus and vaccine structures that initiates the pathological pF4 antibodies," explains Professor Gordon.

"Indeed, the pathways of lethal antibody production in these disorders must be virtually identical and have similar genetic risk factors.

"Our findings have the important clinical implication that lessons learned from VITT are applicable to rare cases of blood clotting after adenovirus (a common cold) infections, as well as having implications for vaccine development," he says.

More information: Jing Jing Wang et al, Antibody Fingerprints Linking Adenoviral Anti-PF4 Disorders, New England Journal of Medicine (2024). DOI: 10.1056/NEJMc2402592

Journal information: New England Journal of Medicine
Citation: Link between COVID-19 vaccine complication and rare 'common cold' blood disease (2024, May 16) retrieved 21 June 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Vaccine blood clotting could be result of genetics


Feedback to editors